Kava

1. 2026-10-19issueIssued info_card
2. 2026-09-07srcThe acute effects of kava and oxazepam on anxiety, mood, neurocognition; and genetic correlates: a randomized, placebo-controlled, double-blind study
3. 2026-09-07srcClinical assessment of CYP2D6-mediated herb-drug interactions in humans: effects of milk thistle, black cohosh, goldenseal, kava kava, St. John's wort, and Echinacea
4. 2026-09-07srcKava and kava hepatotoxicity: requirements for novel experimental, ethnobotanical and clinical studies based on a review of the evidence
5. 2026-09-07srcAre mould hepatotoxins responsible for kava hepatotoxicity?
6. 2026-09-07srcEffect of kava (Piper methysticum) on peripheral gene expression among individuals with generalized anxiety disorder
7. 2026-09-07srcSevere kava withdrawal managed with phenobarbital
8. 2026-09-07srcKava hepatotoxicity: comparison of aqueous, ethanolic, acetonic kava extracts and kava-herbs mixtures
9. 2026-09-07srcFlavokawain A inhibits Cytochrome P450 in in vitro metabolic and inhibitory investigations
10. 2026-09-07srcClinical pharmacokinetics of kavalactones after oral dosing of standardized kava extract in healthy volunteers
11. 2026-09-07srcKava hepatotoxicity solution: A six-point plan for new kava standardization
12. 2026-09-07srcLiver transplantation and the use of KAVA: Case report
13. 2026-09-07srcConstituents in kava extracts potentially involved in hepatotoxicity: a review
14. 2026-09-07srcEvaluation of the Effects of Extracts Containing Valeriana officinalis and Piper methysticum on the Activities of Cytochrome P450 3A and P-Glycoprotein
15. 2026-09-07srcRe-introduction of kava (Piper methysticum) to the EU: is there a way forward?
16. 2026-09-07srcGerman Kava Ban Lifted by Court: The Alleged Hepatotoxicity of Kava (Piper methysticum) as a Case of Ill-Defined Herbal Drug Identity, Lacking Quality Control, and Misguided Regulatory Politics
17. 2026-09-07srcDoes a medicinal dose of kava impair driving? A randomized, placebo-controlled, double-blind study
18. 2026-09-07srcKavain Interference with Amphetamine Immunoassay
19. 2026-09-07srcKava hepatotoxicity: a clinical survey and critical analysis of 26 suspected cases
20. 2026-09-07srcGlobal Perspectives on Kava: A Narrative Systematic Review of the Health Effects, Economic and Social Impacts and Policy Considerations
21. 2026-09-07srcKava hepatotoxicity in traditional and modern use: the presumed Pacific kava paradox hypothesis revisited
22. 2026-09-07srcToxic hepatitis after consumption of traditional kava preparation
23. 2026-09-07srcBiological Activity, Hepatotoxicity, and Structure-Activity Relationship of Kavalactones and Flavokavins, the Two Main Bioactive Components in Kava
24. 2026-09-07srcKava for generalised anxiety disorder: A 16-week double-blind, randomised, placebo-controlled study
25. 2026-09-07srcKavain, the Major Constituent of the Anxiolytic Kava Extract, Potentiates GABAA Receptors: Functional Characteristics and Molecular Mechanism
26. 2026-09-07srcKava: a comprehensive review of efficacy, safety, and psychopharmacology
27. 2026-09-07srcHepatotoxicity Induced by the 3Ks: Kava, Kratom and Khat
28. 2026-09-07srcKava as a Clinical Nutrient: Promises and Challenges
29. 2026-09-07srcNeuroimaging Insights: Kava's (Piper methysticum) Effect on Dorsal Anterior Cingulate Cortex GABA in Generalized Anxiety Disorder
30. 2026-09-07srcKava Hepatotoxicity (letter)
31. 2026-09-07srcEfficacy of kava extract for treating anxiety: systematic review and meta-analysis
32. 2026-09-07srcKava extract for treating anxiety (Cochrane review)
33. 2026-09-07srcTherapeutic potential of kava in the treatment of anxiety disorders
34. 2026-09-07srcAcute hepatitis induced by kava kava
35. 2026-09-07srcIn vitro toxicity of kava alkaloid, pipermethystine, in HepG2 cells compared to kavalactones
36. 2026-09-07srcIn vivo effects of goldenseal, kava kava, black cohosh, and valerian on human cytochrome P450 1A2, 2D6, 2E1, and 3A4/5 phenotypes
37. 2026-09-07srcMeta-analysis of the efficacy of the acetonic kava-kava extract WS1490 in patients with non-psychotic anxiety disorders
38. 2026-09-07srcPotential for interaction of kava and St. John's wort with drugs
39. 2026-09-07srcPharmacokinetics and disposition of the kavalactone kawain: interaction with kava extract and kavalactones in vivo and in vitro
40. 2026-09-07srcIn vitro cytotoxicity of nonpolar constituents from different parts of kava plant
41. 2026-09-07srcEffect of goldenseal and kava kava supplementation on digoxin pharmacokinetics in humans
42. 2026-09-07srcSupplementation with goldenseal, but not kava kava, inhibits human CYP3A activity in vivo
43. 2026-09-07srcComa from the health food store: interaction between kava and alprazolam
44. 2026-09-07srcEffects of kawain and dihydromethysticin on field potential changes in the hippocampus
45. 2026-09-04issueIssued emergency
46. 2026-09-04issueIssued info_card
47. 2026-09-04issueIssued notice
48. 2026-07-03proposaldependence · taper
49. 2026-06-04proposal17 value proposals approved togetherone review action inferred from a shared reviewer and instant — the graph records one activity per proposal
50. 2026-06-04publicationPublication — backfill
51. 2026-05-13revisionRevision 2
52. 2026-05-13absenceSearched PubMed for "Piper methysticum kava taxonomy botanical identity" — no results
53. 2026-05-13absenceSearched PubMed for "kava ethnobotany traditional use Pacific Island history" — no results
54. 2026-05-13absenceSearched PubMed for "kavalactone kavapyrone chemical constituents concentration HPLC" — no results
55. 2026-05-13absenceSearched PubMed for "kava kavalactone pharmacokinetics bioavailability absorption metabolism" — no results
56. 2026-05-13genGeneration — pipeline-v5 · with 3 morepipeline-v5
57. 2026-05-13rungeneration run
58. 2026-03-17importImported from Curiosity v1
59. 2026-03-17publicationPublication — backfill
60. 2026-03-17revisionRevision 1

The same entries, as forms: six forms.